Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ: ALNY )

240.69 -1.06 (-0.44%)
Streaming Delayed Price Updated: 1:16 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years
Via Benzinga
The 3 Best Gene Editing Stocks to Buy in August 2024
These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases. 
Via InvestorPlace
Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82
On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82. 
Via Investor's Business Daily
How Is The Market Feeling About Alnylam Pharmaceuticals?
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $4,100 Today
Via Benzinga
Peering Into Alnylam Pharmaceuticals's Recent Short Interest
Via Benzinga
Peering Into Alnylam Pharmaceuticals's Recent Short Interest
Via Benzinga
DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio?
Top 10 stocks with highest gains last week, including Exact Sciences, Alnylam Pharmaceuticals, Resmed, Coca-Cola Consolidated, DexCom, Sprouts Farmers Market, UL Solutions, Labcorp Holdings, C.H.... 
Via Benzinga
Air Products Posts Upbeat Earnings, Joins Meta, Exact Sciences, Shake Shack, Clearwater Analytics And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety... 
Via Benzinga
Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Stock Is a Blockbuster Biopharma In the Making
Alnylam stock could significantly pad its initial gains if vutrisiran gains expedited approval to hit the market. 
Via InvestorPlace
35% Surge Just the Beginning? Alnylam’s Stock Poised for Massive Gains on Heart Drug Success.
Alnylam Pharmaceuticals stock recently popped and could continue to move higher on Alnylam Pharmaceuticals' cardiovascular drug announcement. 
Via InvestorPlace
7 Cheap Biotech Stocks With Major Upside Potential
While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks. 
Via InvestorPlace
Down 55%, Is Pfizer a Good Dividend Stock to Buy on the Dip?
Shares of the world's largest drugmaker offer a dividend yield above 6% at recent prices. 
Via The Motley Fool
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs. 
Via Benzinga
Topics ETFs
$100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows
June saw gains in the U.S. stock market, with tech and biotech leading the way. Semiconductor ETFs saw strong inflows, while utilities lagged. 
Via Benzinga
Topics ETFs
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Rivian Automotive And Carvana Were Among The 10 Biggest Large Cap Gainers Last Week (June 23-June 29): Are These In Your Portfolio?
The top 10 large-cap stocks in the last week were RIVN, CUK, FDX, IOT, SUZ, CVNA, FTAI, RDDT, MDB, and ALNY. Many analysts have raised their price forecasts for these stocks. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Nvidia, Affirm Holdings, Carnival Corp, Alnylam Pharmaceuticals, Tesla: Why These 5 Stocks Are On Investors' Radars Today
On Monday, major U.S. indices showed mixed performance. The Dow Jones Industrial Average closed up by nearly 0.7% at 39,411.21, 
Via Benzinga
Topics Stocks
Exposures US Equities
Semiconductor, Nvidia Woes Deepen; Nasdaq 100 Slips, Dow Rallies; Bitcoin Sinks To $60,400: What's Driving Markets Monday?
Wall Street faces a continuation of last week’s trend during Monday’s morning trading, with semiconductor stocks selling off heavily and dragging down the tech sector, while the broader market remains... 
Via Benzinga
Topics Stocks
Exposures US Equities
Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears
A 2024 coffee recall is in effect for products made by Snapchill LLC due to concerns of botulism from the FDA for hundreds of canned coffees. 
Via InvestorPlace
Exposures Product Safety
Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success
The challenge for Alnylam now will be to find and diagnose patients with the condition known as ATTR-CM, which is considered rare. 
Via InvestorPlace
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
Alnylam Pharmaceuticals reports positive results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyopathy. The trial showed significant reductions in mortality and... 
Via Benzinga
Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug
The companies are working on treatments for ATTR amyloidosis with cardiomyopathy. 
Via Investor's Business Daily
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.